Molecular Mechanisms of Gastrin Mediated Pathways in Gastric Cancer Cells
胃癌细胞胃泌素介导途径的分子机制
基本信息
- 批准号:8045809
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-01-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adenocarcinoma CellAdverse effectsAgingAnimal ModelBiological AssayCancer Cell GrowthCancer EtiologyCarcinomaCause of DeathCell Culture TechniquesCell LineCell ProliferationCell physiologyCessation of lifeCholecystokinin B ReceptorClinicalColorectal CancerConditioned Culture MediaDNADataDetectionDevelopmentDiseaseDisease ProgressionEventExcisionFutureGastrinsGastrointestinal NeoplasmsGastrointestinal PhysiologyGastrointestinal tract structureGene SilencingGlycineGoalsGrantGrowthGrowth FactorHelicobacter InfectionsImmunoprecipitationIn VitroIngestionInjection of therapeutic agentInterleukin-10InvestigationJUN geneLeadLuciferasesMAP Kinase GeneMAPK14 geneMAPK8 geneMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMediatingMediator of activation proteinMolecularMusNeoplasm MetastasisOperative Surgical ProceduresPathway interactionsPatientsPharmaceutical PreparationsPhosphotransferasesProceduresProcessProton Pump InhibitorsResearchResearch DesignRisk FactorsRoleSerumSignal PathwaySignal TransductionStomachStomach CarcinomaTailTechnologyTherapeuticTransfectionUnited StatesVeinsVeteransXenograft procedurebasecancer cellcell motilitycell typecombatcytokinedesigndrug developmenteffective therapygastrointestinalin vivoinhibitor/antagonistmalignant stomach neoplasmmembermigrationmixed lineage kinase 3mortalitymouse modelneoplastic celloverexpressionpatient populationpeptide hormoneprogastrinsubcutaneoustumortumor progression
项目摘要
DESCRIPTION (provided by applicant):
Rationale: Gastric cancer is a leading cause of cancer death and ranks second in the overall cancer mortality worldwide. The GI (gastrointestinal) peptide hormone gastrin (both processed and unprocessed forms) is regarded as an important contributing factor towards the patho-physiology of GI malignancies. Studies with mice over-expressing the mature amidated form of gastrin were shown to produce invasive gastric carcinoma, which synergized with Helicobacter infection to promote carcinoma progression. These effects of gastrin pose a major clinical concern, since an increase in serum gastrin levels is a common side effect of the use of proton pump inhibitors (PPIs) or Helicobacter pylori infection. Thus the signaling pathways by which gastrin mediates cancer progression, though still poorly understood, represent an important target for the development of drugs to combat gastric cancer. The major focus of this proposal is to elucidate the signaling mechanism by which gastrin promotes tumor progression and metastasis in gastric cancer cells, and to target this signaling axis in mouse models of gastric cancer. Our recent studies indicated that: (i) treatment with amidated gastrin (G17) potently induces gastric cancer cell migration and invasion; (ii) G17-induced migration is associated with activation of all 3 MAPK pathways including ERK, p38 and JNK; (iii) G17 stimulation results in activation of the MAP3K member MLK3, which is an upstream activator of JNK, (iv) G17-induced migration operates via MLK3/JNK1 axis in vitro; (v) G17 activates the JNK downstream c-Jun via releasing some factor and (vi) conditioned media obtained from G17-treated gastric cancer cells showed increased IL-10 release by G17. Hypothesis: Based on these preliminary data we hypothesize that G17-induced gastric cancer cell growth (proliferation), migration and invasion operates through activation of MLK3/JNK1 signaling. Specific Objectives: To elucidate the signaling mechanism by which G17 induces gastric carcinoma progression, we propose the following 3 specific aims: (1) to determine whether G17-induced migration, invasion, EMT and growth involve the MLK3/JNK1 axis in vitro; (2) to elucidate the mechanism by which G17 activates MLK3/JNK1 axis and the role of cytokines in mediating this; (3) to determine the effect of hypergastrinemia on the progression of gastric cancer in vivo and the effect of inhibition of MLK3/JNK1 pathways, either by pharmacological inhibitors or via gene silencing on this progression. Procedures to be used: The proposed studies will be performed using a broad range of technical approaches, including migration, invasion and cell proliferation assays, Western analyses, DNA transfection, luciferase and kinase assays, immunoprecipitation, SiRNA technology, subcutaneous xenografts and tail vein injections. Significance of potential new findings: The fact that hypergastrinemia promotes tumor progression poses a major clinical concern in the setting of increased PPI use and H.pylori infection. No information is currently available regarding the involvement of MLK3/JNK axis in promoting gastric cancer growth and progression. The successful completion of these studies will determine whether this axis promotes gastrin-induced gastric carcinoma progression. The results from these studies can further promote the detailed investigation of the potential use of available MLK/JNK pathway inhibitors as safe, noninvasive drugs for the treatment of patients with gastric as well as other gastrin- dependent GI malignancies.
PUBLIC HEALTH RELEVANCE:
The proposed studies are of significant importance to the VA patient population, since GI cancer is prevalent among aging veterans. Surgical resection is the only form of therapy currently available to treat gastric or GI cancers, which is effective only if the tumor is detected early. The long-term focus of our studies is to develop a noninvasive form of curative therapy for treating VA patients with gastric or other GI malignancies. To achieve this goal, it is important to gain a better understanding of the molecular events that lead to the development and progression of these diseases. Since the GI peptide hormone gastrin is known to promote progression of gastric cancers, the studies described here will be focused on understanding the detailed mechanism by which gastrin mediates this function. These studies will be performed utilizing both cell culture (in vitro) and animal models of gastric cancer (in vivo). Once these mediators are identified, drugs that can target these mediators can be designed in the future, and utilized as safer, noninvasive therapeutic drugs for treating gastric cancer.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BASABI RANA其他文献
BASABI RANA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BASABI RANA', 18)}}的其他基金
Mixed Lineage Kinase 3 and cytokine signaling axis in hepatocellular carcinoma
肝细胞癌中的混合谱系激酶 3 和细胞因子信号轴
- 批准号:
10527344 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mixed Lineage Kinase 3 and cytokine signaling axis in hepatocellular carcinoma
肝细胞癌中的混合谱系激酶 3 和细胞因子信号轴
- 批准号:
10365639 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
9032316 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
10038787 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
10324547 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Elucidation of MLK3 Signaling in Hepatocellular Carcinoma
肝细胞癌中 MLK3 信号传导的阐明
- 批准号:
9256218 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
8854052 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
9487175 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
8694742 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Role of beta-catenin in apoptosis resistance of hepatocellular carcinoma
β-catenin在肝细胞癌凋亡抵抗中的作用
- 批准号:
9190200 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
-- - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual